Humans ; Adamantinoma/surgery* ; Bone Diseases, Developmental ; Bone Neoplasms/surgery* ; Tibia/surgery*

Brown tumors also called as osteoclastomas, are rare nonneoplastic lesions that arise in the setting of primary or secondary hyperparathyroidism. Parathyroid adenomas or hyperplasia constitute the major Brown tumor source in primary hyperparathyroidism while chronic renal failure is the leading cause in secondary hyperparathyroidism. Most of the patients with the diagnosis of primary hyperparathyroidism present with kidney stones or isolated hypercalcemia. However, nearly one third of patients are asymptomatic and hypercalcemia is found incidentally. Skeletal involvement such as generalized osteopenia, bone resorption, bone cysts and Brown tumors are seen on the late phase of hyperparathyroidism. The symptoms include axial pain, radiculopathy, myelopathy and myeloradiculopathy according to their locations. Plasmocytoma, lymphoma, giant cell tumors and metastates should be ruled out in the differential diagnosis of Brown tumors. Treatment of Brown tumors involve both the management of hyperparathyroidism and neural decompression. The authors report a very rare spinal Brown tumor case, arisen as the initial manifestation of primary hyperparathyroidism that leads to acute paraparesis.
Bone Cysts ; Bone Diseases, Metabolic ; Bone Resorption ; Decompression ; Diagnosis ; Diagnosis, Differential ; Giant Cell Tumors ; Humans ; Hypercalcemia ; Hyperparathyroidism ; Hyperparathyroidism, Primary* ; Hyperparathyroidism, Secondary ; Hyperplasia ; Kidney Calculi ; Kidney Failure, Chronic ; Lymphoma ; Paraparesis ; Parathyroid Neoplasms ; Plasmacytoma ; Radiculopathy ; Spinal Cord Diseases ; Spine*

Background: Breast cancer, chemotherapy and endocrine treatment are risk factors for osteoporosis. Dual-energy x-ray absorptiometry (DXA) remains the gold standard in the diagnosis of osteoporosis. A quantitative computed tomography (QCT) with a bone mineral density analysis software on the whole abdomen CT may be used for screening osteoporosis without additional radiation exposure or cost. Objective: To determine the accuracy of QCT in detecting osteoporosis among breast cancer patients using DXA as gold standard. Methods: This is a cross-sectional analytic study of 76 Filipino women with breast cancer who underwent both DXA and whole abdomen CT scans. The DXA measurements were obtained using Lunar iDXA manufactured by GE Healthcare while the QCT measurements were made using the BMD analysis software available in the Philips Extended Brilliance Workspace post-processing system. Results: Out of the 76 Filipino women with breast cancer, 92% were menopausal women with mean age of 58.9 (SD 8.7) years, 69.7% had IDCA and 94.7% had mastectomy. Majority had normal BMD (44.7%), 34.2% had osteopenia and 21.1% had osteoporosis based on DXA. QCT has 90% (95% CI: 55.5-99.8) sensitivity, 63.6% (95% CI: 30.1- 89.1) specificity, 69.2% (95% CI: 50.1-83.5) PPV, 87.5 (95% CI:50.8-97.9) NPV, 2.5 (95% CI:1.1-5.6) LR(+) and 0.16 (95% CI:0.02-1.06) LR (-). Conclusion The prevalence of osteoporosis and osteopenia among Filipino women with breast cancer was 21.1% and 34.2%. The sensitivity and specificity of QCT in detecting osteoporosis was 90% and 63.6%.
Osteoporosis ; Bone Diseases, Metabolic ; Breast Neoplasms

Objective. To present preliminary data on the effects of intravenous pamidronate in children with moderate to severe Osteogenesis Imperfecta (OI). Methods. This is a restrospective study wherein a review of medical records and available serial radiographs of children (N=14) with moderate to severe IO started on pamidronate from 2006 to 2010 was done. Results. Two children have IO Type I, 8 have IO Type III and 4 have IO Type IV. At baseline, 2 had normal height, 8 had height less than minus 2SD and the rest with less than minus 1SD. Twelve out of 14 had vertebral compression fractures. Mean age at start of pamidronate was 5.4 years (range 0.5-11 years). First infusion fever in five patients and transient generalized macular rash in one child were noted. Serum calcium and phosphorus levels were normal at baseline and remained stable. Based on parental report, improvement of motor function was noted. In the 10 children who had at least a year of treatment, long bone fractures decreased from mean annualized fracture rate of 2.6 at baseline to 0.9. In patients with vertebral compression fractures, serial radiographs showed improvement of vertebral shape. Conclusion. This preliminary study shows that treatment was generally well tolerated and led to decrease in long bone fractures, improved vertebral shape and improved function.
Human ; Male ; Female ; Child ; Child Preschool ; PAMIDRONATE ; OSTEOGENESIS IMPERFECTA ; MUSCULOSKELETAL DISEASES ; BONE DISEASES ; BONE DISEASES, DEVELOPMENTAL ; BONE DISEASES, METABOLIC ; OSTEOCHONDRODYSPLASIAS ; THERAPEUTICS ; THERAPY ; OSTEOPOROSIS

Bone remodeling is the fundamental means by which the quality as well as quantity of the skeleton is maintained throughout adult life. When bone remodeling goes awry, a metabolic bone disease such as osteoporosis ensues. Among multiple phases of the complex remodeling process, we focus in this review on factors and mechanisms that are involved in the coupling of bone formation to preceding resorption.
Adult ; Bone Diseases, Metabolic ; Bone Remodeling ; Bone Resorption* ; Humans ; Osteoblasts* ; Osteoclasts* ; Osteogenesis ; Osteoporosis ; Skeleton

OBJECTIVES: To assess the clinical efficacy of once-yearly treatment with Zoledronic acid in patients with osteopenia. MATERIALS AND METHODS: From June 2009 to November 2011, patients diagnosed with osteopenia were applied to fracture risk assessment tool (FRAX). Among them, 40 patients who showed high possibility of osteoporotic fracture were selected and treated with intravenous zoledronic acid once-yearly. At the baseline and after one year of injection of zoledronate, we measured the changes in the bone mineral density (BMD) and bone turnover markers In addition, we analyzed the side effects and thereby assessed the drug safety.
Bone Density ; Bone Diseases, Metabolic ; Bone Resorption ; Hip ; Humans ; Osteocalcin ; Osteoporotic Fractures ; Risk Assessment

Intraosseous ganglion is a rare disease and identified as a cystic lesion on plain radiograph. One case ofintraosseous ganglion is examined by plain radiography and CT and findings are analyzed.
Bone Cysts ; Ganglion Cysts ; Radiography ; Rare Diseases

Patients with gastrointestinal disease (GI) are at risk for osteopenia or osteoporosis, which can lead to fractures. Although these patients may be at risk from a young age, gastroenterologists often overlook this fact in practice. There are well-known GI diseases associated with osteopenia and osteoporosis, such as the post-gastrectomy state, inflammatory bowel disease (IBD), and celiac disease. As there is an increase in the prevalence of IBD patients, newly diagnosed celiac disease in adulthood, and gastric cancer survivors following gastrectomy, bone disease in these patients becomes an important issue. Here, we have discussed osteoporosis and fractures in GI disease, especially in the post-gastrectomy state, IBD, and celiac disease. Although the pathogenesis of bone loss in each disease has not been fully identified, we have confirmed that the prevalence of osteoporosis and fractures in each of these diseases is high. There are scarce studies comparing the prevalence of osteoporosis or osteoporotic fractures in GI disease patients with studies in postmenopausal women, and specific guidelines for their management in each disease have not been established. Intensive surveillance and management are needed to ensure that these patients attain peak bone mass for age and sex to prevent fractures.
Bone Diseases ; Bone Diseases, Metabolic ; Celiac Disease ; Female ; Gastrectomy ; Gastrointestinal Diseases* ; Humans ; Inflammatory Bowel Diseases ; Osteoporosis* ; Osteoporotic Fractures* ; Prevalence ; Stomach Neoplasms ; Survivors

BACKGROUND: Botulinum toxin injection on the masticatory muscle induces the osteopenic condition on the ipsilateral condyle. Bisphosphonate suppresses bone resorption and is used to treat osteopenic or osteoporotic condition. This study aimed to evaluate the effect of bisphosphonate administration on prevention of condylar resorption and botulinum toxin A-induced disuse osteopenia in rats. RESULTS: The volume of the condyle and bone volume/tissue volume (BV/TV, %) showed a strong tendency towards statistical significance (p = 0.052 and 0.058). Trabecular thickness (Tb.Th, mm) and trabecular number (Tb.N, 1/mm) were significantly smaller in the Botox group than in the other groups (p < 0.05). The volume of the condyle and BV/TV in the bisphosphonate 100 and bisphosphonate 200 groups showed similar values when compared with the control group. CONCLUSION: Bisphosphonate administration after botulinum toxin A injection in the masticatory muscles appears to prevent condyle resorption and botulinum toxin-induced disuse osteopenia in rats.
Animals ; Bone Diseases, Metabolic ; Bone Resorption ; Botulinum Toxins ; Mandibular Condyle ; Masticatory Muscles ; Rats ; Temporomandibular Joint

PURPOSE: The purpose of this study was to investigate the distribution of diseases and the orthopedic procedures performed in patients with genetic and metabolic bone diseases. MATERIALS AND METHODS: One hundred and fifty-three patients, who were admitted to the orthopedic ward under a diagnosis of genetic or metabolic bone disease from January 1990 to December 2000, were investigated. Their medical records, radiographs and laboratory data were reviewed, and orthopedic procedures analyzed. RESULTS: One hundred and fifty-one cases were diagnosed with specific diseases, while 2 remained unspecified. Achondroplasia, multiple epiphyseal dysplasia-pseudoachondroplasia and metaphyseal chondrodysplasia were common among the skeletal dysplasia cases. Hypophosphatemic rickets and osteogenesis imperfecta were common diseases among the metabolic and connective tissue categories. Limb lengthening was frequently performed in achondroplasia and in hypophosphatemic rickets, while deformity correction and hip surgery were frequent in multiple epiphyseal dysplasia - pseudoachondroplasia and metaphyseal chondrodysplasia. CONCLUSION: In genetic and metabolic bone diseases, only a limited number of clinical problems can be solved by orthopedic procedures. As new techniques are developed the pattern of orthopedic treatmen may change.
Achondroplasia ; Bone Diseases, Metabolic* ; Congenital Abnormalities ; Connective Tissue ; Diagnosis ; Extremities ; Hip ; Humans ; Medical Records ; Orthopedic Procedures ; Orthopedics* ; Osteochondrodysplasias ; Osteogenesis Imperfecta ; Rickets, Hypophosphatemic